China plans to merge CFDA into a massive market-supervision agency, while maintaining drug regulation as a separate bureau under it.

TaiMed Biologics' new HIV med, just approved by the FDA, will be produced by WuXi Biologics in the first Chinese biologics plant approved by the FDA.

The FDA issued a warning letter to Chinese OTC drugmaker Zhejiang Ludao Technology, citing data integrity and product testing issues.

Trogarzo (ibalizumab-uiyk) is the first HIV therapy with a novel mechanism of action in more than 10 years.

Regulatory problems are piling up for the sterile manufacturing operations of India’s Aurobindo, which has had another plant cited by the FDA.

Shionogi's Roche-partnered Xofluza, a one-time, single-dose regimen, probably won't win U.S. approval till next winter.

Biocon and Mylan have hit another manufacturing snag on their march toward an FDA nod for their copy of Sanofi's blockbuster Lantus.  

After two refusals from Sanofi to provide a refund for the Dengvaxia program, officials in the Philippines say they are getting ready to sue.

After a year of remediation, an Indian drugmaker has worked its way out from under an FDA warning letter issued for its sterile injectables operation.